Clinical Trials Browser

Phase 1/2 × interferon gamma-1b × Dermatologic × Clear all

NCT03747484 2025-03-06

Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Phase 1/2 Terminated

7 enrolled 15 charts

Neoplasm Metastasis, Carcinoma, Merkel Cell